🎄✨ Happy Holidays from CSHP! ✨🎄 May this holiday season bring you joy, peace, and precious moments with loved ones. Here’s to a happy, healthy, and successful New Year ahead! 🎉🥂 Thank you for being part of our CSHP family. We look forward to another amazing year together! #CSHP #HappyHolidays
California Society of Health - System Pharmacists
Hospitals and Health Care
Sacramento, California 2,211 followers
Leaders in Wellness, Patient Safety and Optimal Use of Medications.
About us
California Society of Health-System Pharmacists Founded in 1962 the association represents thousands of pharmacists, pharmacy technicians, and students across California who serve patients and the public through promotion of wellness, patient safety, and the optimal use of medications. CSHP members practice in all types of settings, including but not limited to; hospitals, health systems, clinics, ambulatory care, long term care, retail, community, academia, managed care, and home healthcare.
- Website
-
https://linktr.ee/cshp_hq
External link for California Society of Health - System Pharmacists
- Industry
- Hospitals and Health Care
- Company size
- 2-10 employees
- Headquarters
- Sacramento, California
- Type
- Nonprofit
- Founded
- 1962
- Specialties
- Pharmacists, Pharmacy Technicians, and Pharmacy Professionals
Locations
-
Primary
1314 H St
100
Sacramento, California 95814, US
Employees at California Society of Health - System Pharmacists
-
Loriann De Martini, Pharm.D., M.P.H., BCGP
Chief Executive Officer - California Society of Health System Phamacists
-
Kathy Daly
Application Analyst at Scripps Health
-
Betty Jue
Retired Health-System Pharmacist, Manager, Educator, and Project Manager
-
Diana Park, PharmD, BCEMP, APh, FCSHP
Clinical Pharmacist
Updates
-
CSHP is delighted to announce the results of our recent Board of Directors election. We extend our heartfelt congratulations to the following individuals who will join our leadership team! These accomplished leaders will be officially installed next month. We look forward to their contributions as they help guide CSHP in advancing pharmacy practice and supporting our members across California. Read our full announcement ➡️ https://bit.ly/3DuKEQC
-
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease The U.S. Food and Drug Administration (FDA) has approved a new drug to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil (remestemcel-L-rknd) is an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy. It is administered as a suspension for intravenous infusion and is the first FDA-approved MSC therapy. The safety and effectiveness of Ryoncil were evaluated in a multicenter, single-arm study in 54 pediatric study participants with SR-aGVHD after undergoing allo-HSCT. The study participants received intravenous infusion of Ryoncil twice weekly for four consecutive weeks, for a total of eight infusions, and the efficacy was based primarily on the rate and duration of response to treatment 28 days after initiating Ryoncil. The study results demonstrated that sixteen study participants (30%) had a complete response to treatment 28 days after receiving Ryoncil, while 22 study participants (41%) had a partial response. Precautions and warnings for Ryoncil include contraindication with patients with known hypersensitivity to dimethyl sulfoxide or porcine and bovine proteins. Before starting the infusion for Ryoncil, patients should be premedicated with corticosteroids and antihistamines. The treating physician should monitor patients during the infusion, and the infusion should be discontinued if there is any evidence of a reaction which may include dyspnea, hypotension, fever, tachypnea, cyanosis, hypoxia, and hypersensitivity. The most common adverse reactions were infections, fever, hemorrhage, edema, abdominal pain, and hypertension. Complications may occur following treatment with Ryoncil such as hypersensitivity and acute infusion reactions, transmission of infectious disease or agents, and ectopic tissue formation. View the FDA’s announcement here: https://lnkd.in/eH63UdNn
-
California Society of Health - System Pharmacists reposted this
Last Monday, I had the opportunity to not only attend my first San Gabriel Valley Society of Health-System Pharmacists (SGVSHP) Board Meeting but, also learn about a new FDA-approved medication to treat Schizophrenia in adults! I'd like to thank Dr. Duc Bach, for extending me the opportunity to take part in the meeting to discuss the chapter's finances, upcoming collaborations, as well as the logistics of their most important event; Installation Banquet/Night of Industry. Always, happy to be apart of the process! Very big thank you to Dr. Wilson Liu, and Bristol Myers Squibb, for their hospitality and informative presentation on Cobenfy. Having learned about it's unique mechanism of action, and the multiple studies done on it, Cobenfy points to a new direction in psychiatric treatment for adults who have Schizophrenia. #studentpharmacist #sgvshp #BMS #Cobenfy #Schizophrenia
-
California Society of Health - System Pharmacists reposted this
Kanika Bhandari and Stephanie Kourtakis, esteemed faculty in KGI's PharmD program, made an impact at the California Society of Health-System Pharmacists (CSHP) Seminar 2024 in Palm Springs. This premier annual event brings together pharmacy professionals for continuing education, networking, and advancement of pharmacy practice. Their active involvement demonstrates KGI's commitment to shaping the future of pharmacy education and practice. Repost from Kanika Bhandari I cannot even begin to express how wonderful of a time I had at Seminar 2024 hosted by California Society of Health - System Pharmacists in Palm Springs, CA! It is so exciting to have this opportunity every year to reconnect with some of my favorite people in pharmacy! I had the best time taking on new roles this year by judging the Clinical Skills Competition and also volunteering for Quiz Bowl. For those of you who made it out to our continuing education session, “Are GLPs the One? Overview and Adverse Effects of GLPs-1 RAs,” we thank you for making it a full house! My colleague, Stephanie Kourtakis, and I had a wonderful presentation full of an engaging audience and remarkable clinical questions. And, of course, since the conference fell on Halloween this year, we had to show up in costume. 👯♀️ Here are just a *few* photos of the great times that were had. Until next year! 😊 #PharmD #PharmacyEducation #CSHP #KeckGrad #HealthcareInnovation
-
This week we are proud to spotlight Dr. Jay Rho, CSHP's 2024 Distinguished Service Award and Honorary Member recipient! Hear about Dr. Rho's 42-year career journey and how he learned that the role of the pharmacist would not expand on its own and remain status quo unless the next generation of pharmacists would work to push the limits of our profession to allow pharmacists to perform at the top of their scope of practice. Read his full spotlight ➡️ https://bit.ly/3BEvRCf
-
FDA Approves New Drugs for Congenital Adrenal Hyperplasia The U.S. Food and Drug Administration (FDA) has approved a new drug to control androgen levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). Crenessity (crinecerfont) is a corticotropin-releasing factor type 1 receptor antagonist indicated as an adjunctive treatment to glucocorticoid replacement. It is administered as an oral capsule taken twice daily with food. The efficacy of Crenessity was based on two randomized, double-blind, placebo-controlled trials in 182 adults and 103 children with classic CAH. The first trial involved 122 adults who received Crenessity twice daily and 60 who received a placebo twice daily for 24 weeks and the primary measure of efficacy was determined by the change from baseline in the total glucocorticoid daily dose while maintaining androstenedione control at the end of the trial. The group that received Crenessity reduced their daily glucocorticoid dose by 27% while maintaining control of androstenedione levels, compared to a 10% daily glucocorticoid dose reduction in the placebo group. The second trial involved 69 pediatric patients who received Crenessity twice daily and 34 received a placebo twice daily for 28 weeks, and the primary measure of efficacy was the change from baseline in serum androstenedione at week 4. The group that received Crenessity experienced a statistically significant reduction from baseline in serum androstenedione, compared to an average increase from baseline in the placebo group. Precautions and warnings for Crenessity include acute adrenal insufficiency and hypersensitivity to Crenessity’s active ingredient or any of its components. Crenessity should not be used at the same time as drugs that activate that enzyme can decrease the amount of Crenessity exposure and reduce Crenessity’s efficacy. The most common adverse reactions were fatigue, dizziness, and arthralgia for adults. For pediatrics, the most common adverse reactions were headache, abdominal pain, and fatigue. View the FDA’s announcement here: https://lnkd.in/gf_GeGDe
-
Seminar 2025 is back! 🗓️☀️ We are returning to sunny San Diego from October 30th to November 2nd at the BRAND NEW Gaylord Pacific Resort & Convention Center! 🌴 More details to come. #Seminar2025 #Pharmacy
-
Patient Safety Champion Alert! 🚨 Sue Sheridan, a leading voice in patient safety, will be at #PCPSC2025! Don't miss her insights on improving patient care. Read more about Sue ➡️ https://lnkd.in/g7PfmKN5 Registration & Conference details ➡️ https://lnkd.in/gwUHXwyF
-
Our Board of Directors (BOD) is the governing authority of CSHP. Each month, our BOD convenes to discuss upcoming policy, the association, and much more! View our new 2024 Q3 Meeting Highlights + more ➡️ https://lnkd.in/gRnKh7Qz (Member Login Required)